Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Washington Blvd STAMFORD CT 06902-9302 |
Tel: | N/A |
Website: | https://www.springworkstx.com |
IR: | See website |
Key People | ||
Saqib Islam Chief Executive Officer, Director | Francis Perier Chief Financial Officer | Badreddin Edris Chief Operating Officer |
Daniel Pichl Chief People Officer | Tai-an Lin Chief Scientific Officer | Herschel S. Weinstein General Counsel, Secretary |
Bhavesh Ashar Chief Commercial Officer | James Cassidy Chief Medical Officer |
Business Overview |
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors. |
Financial Overview |
For the fiscal year ended 31 December 2023, SpringWorks Therapeutics Inc revenues increased from $0K to $5.4M. Net loss increased 17% to $325.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General & Administrative - Balancing. increase of 51% to $137.4M (expense), Stock-based Compensation in SGA increase of 38% to $60.1M (expense). |
Employees: | 305 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2,734M as of Dec 31, 2023 |
Annual revenue (TTM): | $5.45M as of Dec 31, 2023 |
EBITDA (TTM): | -$341.35M as of Dec 31, 2023 |
Net annual income (TTM): | -$325.10M as of Dec 31, 2023 |
Free cash flow (TTM): | -$230.18M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 74,059,896 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |